Skip to main contentSkip to footer
blood-1813410_1920
Brighton & Sussex Medical School

News and events

The latest news and events from the Haematology Research Group. 

Alessandro Agnarelli2

May 2019

HRG seminar  

All staff, colleagues and friends of the Haematology Research Group were invited to attend a seminar on Friday 10 May. The seminar, titled 'Targeting IRF4 in Multiple Myeloma with epigenetic inhibitors' and sponsored by Fisher Scientific, was presented by Alessandro Agnarelli, a PhD student with the Mancini group. 

Prof Chris Pepper

February 2019

'Game changing' test can predict how people with leukaemia will respond to chemotherapy

The first test to quickly and accurately predict how people will respond to standard treatment for the most common type of leukaemia has been developed by a researcher at BSMS. The technology could guide doctors’ decisions on which drugs to give to patients.

Read more >

blood-1813410_1920

January 2019

New Sussex research group to investigate blood cancers

A new collaborative research group aims to explore the causes of blood cancers and design new treatments. The Haematology Research Group is a network of six labs across the School of Life Sciences at the University of Sussex and BSMS. 

Read more >

HRG news Dec18

December 2018

Research reveals mechanism for leukaemia cell growth prompting hopes for new treatment strategies

A mechanism which drives leukaemia cell growth has been discovered by researchers at the University of Sussex, who believe their findings could help to inform new strategies when it comes to treating the cancer. Acute myeloid leukaemia (AML) is a devastating blood cancer with around 3,000 new cases annually in the UK.

Read more >

HRG news Sept18

September 2018

Search for blood cancer cure receives University funding

A researcher has received funding from the University of Sussex to help discover a cure for an aggressive and incurable type of blood cancer; multiple myeloma. Dr Erika Mancini received more than £19,000 from the University’s Research Development Fund.. 

Read more >